Nils Wilking

ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS

Tommy� Fornander, Björn Cedermark, Anders Mattsson et al. · The Lancet · 1989 · 930 citations

Breast Oncology, Medicine, Gynecology +5

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial

Jonas Bergh, Tom Wiklund, Björn Erikstein et al. · The Lancet · 2000 · 342 citations

Breast Oncology, Oncology, High-risk Breast Cancer +7

The cost of cancer in Europe 2018

Thomas Hofmarcher, Peter Lindgren, Nils Wilking et al. · European Journal of Cancer · 2020 · 305 citations · Full text

Topoisomerase IIα Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in <i>HER-2/neu</i>–Amplified Breast Cancer: Scandinavian Breast Group Trial 9401

Minna Tanner, Jorma Isola, Tom Wiklund et al. · Journal of Clinical Oncology · 2006 · 255 citations · Full text

Correlation of Vascular Endothelial Growth Factor Content With Recurrences, Survival, and First Relapse Site in Primary Node-Positive Breast Carcinoma After Adjuvant Treatment

Barbro Linderholm, Kjell Grankvist, Nils Wilking et al. · Journal of Clinical Oncology · 2000 · 254 citations